The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target.

中文翻译：

---

用于治疗和预防目标的 SARS-CoV-2 刺突糖蛋白的结构。

2019 年冠状病毒病 (COVID-19) 引发的全球危机导致了二战后最严重的经济损失和人员死亡。引起这种疾病的病原体是一种新型病毒，称为严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)。截至2020年12月，全球确诊患者已达8020万，死亡率为2.16%。保护宿主免受 SARS-CoV-2 感染的策略是抑制细胞内病毒复制或阻止病毒进入。我们重点关注负责 SARS-CoV-2 进入宿主细胞的刺突糖蛋白。近日，美国食品药品监督管理局/欧盟药品管理局在缺乏长期临床试验的情况下，通过紧急使用批准，授权一种疫苗和抗体用于治疗COVID-19患者。世界各地都在继续致力于开发预防和治疗药物的商业和学术努力。在这篇综述中，我们对当前有关 SARS-CoV-2 刺突糖蛋白作为治疗靶点的报道提出了看法。